English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)

The Immuno-Oncologic Therapeutic area of Italfarmaco is acknowledged by the Italian oncologic community as a reference point in the specialist sector thanks to the originality of its products, the innovative pharmaceutical solutions and the innovation of experimental protocols.

Hematology and Oncology

Italfarmaco has always developed products for the treatment of tumors and patient support through a constant partnership with Scientific Societies and the most qualified research groups in the oncologic area (solid tumors) as well as in the hematologic area (leukemia, myelomas, lymphomas, bone marrow transplantation). Thanks to the support offered by clinical research, the products manufactured by Italfarmaco today have a scientific literature authoritatively documenting its efficacy and safety extended to all these clinical settings.

  • MYELOSTIM® (lenograstim) is the only glycosylated granulocyte growth factor, indistinguishable from the native human one, effectively enabling to prevent and control bone marrow toxicity caused by the use of chemotherapeutic agents producing neutropenia, and thus facilitating its administration according to the time and doses as scheduled by the specialist.

Treatment of tumors

The company has a well-established experience and expertise in the therapeutic area of endocrinology and neuroendocrine tumors, thanks to the octreotide-based medicinal products. The different pharmaceutical formulations (e.g. pre-filled syringes - TREOJECT®) and different dosage strengths and schedules as well ensure a maximum clinical efficacy and aid patients’ adherence to treatment protocols.

Supportive care in oncology and hematology

Nausea, vomiting, serious chronic pain and neutropenia, causing frequent, often fatal infections, represent the feared and severe complications of chemotherapeutic treatment in patients with tumors, resulting in a worsened Quality of Life or the impossibility of continuing their medical treatment.

  • AKYNZEO® (netupitant/palonosetron) is the first and only fixed-dose antiemetic in combining the new NK-1 antagonist netupitant with the sole antagonist of the second generation of serotonin, palonosetron, already marketed by Italfarmaco since 2006 as ALOXI®. Thanks to its totally innovative oral formulation and to the characteristics of its active ingredients, which act in a synergistic and long acting way, AKYNZEO® is able to ensure the highest levels of safety and efficacy in the prevention of nausea and vomiting, with a single dose ready to use, administered before cancer chemotherapy. AKYNZEO® so simplifies the management of antiemetic prophylaxis and facilitates better compliance with the recommendations of the major international guidelines on the prevention of nausea and vomiting from chemotherapy.
  • For the treatment of severe chronic pain, Italfarmaco has introduced the first transdermal patch patented with double matrix (FENTALGON®), studied to improve the release of the active ingredient and ensure pain control until 72 hours after application.

The Immuno-oncologic therapeutic area of Italfarmaco has always been acknowledged for its innovative products and its constant support to clinical research aimed at optimizing tumor response to treatment and give patients the best possible life conditions.